Engineering NK cells with LNP-enabled IL-2 mRNA transfection: Steps toward affordable precision immuno-therapeutics

The natural killer (NK) cells of the immune system have emerged as potent warriors, capable of targeting and eliminating malignant cells without prior sensitization.1 Work carried out by Pichon and colleagues presents a significant advancement in the field of immunotherapy and in particular in cancer treatment.2 This study encompasses engineering of the innate immune cells, NK cells, toward intrinsically secreting interleukin-2 (IL-2), a critical cytokine that amplifies immune responses by employing a lipid nanoparticle (LNP)-enabled IL-2 mRNA delivery.